Norihiro Watanabe, Assistant Professor at Baylor College of Medicine, shared on LinkedIn:
“I am thrilled to share our latest preprint now available on bioRxiv, focused on enhancing TCR-based immune cell therapy for cancer.
TCR-based cancer cell targeting offers unique advantages over CAR-T therapies, including the ability to target endogenous antigens and high sensitivity in antigen recognition.
However, unlike CAR constructs, TCR-based therapeutic cells often lack crucial costimulatory (signal 2) and cytokine (signal 3) signals.
To address this limitation, we engineered a novel synthetic receptor called the Dual-Stimulatory Receptor (DSR).
This receptor simultaneously delivers both signal 2 and signal 3 to therapeutic T cells, triggered upon T cell receptor engagement (signal 1).
We evaluated the DSR framework across multiple TCR-based immunotherapy platforms, including Transgenic TCRs, T cell engagers, and chimeric TCRs (scFv + TCR).
While it has been a long journey to reach the preprint stage, we are looking forward to the final push required for peer-reviewed publication.
Read the full preprint here: Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies
I would love to hear your thoughts, feedback, or potential collaboration ideas!”
Title: Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies
Authors: Mansi Narula, Johannes Englisch, Cheryl Ou, Tadahiro Honda, Ismael de la Iglesia-San Sebastian, Azlann Arnett, ProfileFeiyan Mo, Maksim Mamonkin, Norihiro Watanabe
Other articles about CAR-T on OncoDaily.